Twenty-four hour efficacy with the dorzolamide/timolol-fixed combination compared with the brimonidine/timolol-fixed combination in primary open-angle glaucoma

Konstas, Anastasios G. P.; Quaranta, Luciano; Yan, David; Mikropoulos, Dimitrios G.; Riva, Ivano; Gill, Navroop; Barton, Keith; Haidich, A-B

doi:10.1038/eye.2011.239

Cited by 24 publications

(25 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some other fixed-combination glaucoma medications have also demonstrated 24-hour control of IOP. For example, fixed combinations of dorzolamide and timolol, and brimonidine and timolol both significantly decrease IOP from baseline (mean IOP reduction: 2.9 mmHg and 2.2 mmHg, respectively) 59. However, IOP reductions were greater during the night (6 pm and 2 am) with dorzolamide and timolol compared with brimonidine and timolol, which was to be expected given the decreased evening efficacy of both components 58,59.…”

Section: Efficacy Of Bbfcmentioning

confidence: 86%

“…For example, fixed combinations of dorzolamide and timolol, and brimonidine and timolol both significantly decrease IOP from baseline (mean IOP reduction: 2.9 mmHg and 2.2 mmHg, respectively) 59. However, IOP reductions were greater during the night (6 pm and 2 am) with dorzolamide and timolol compared with brimonidine and timolol, which was to be expected given the decreased evening efficacy of both components 58,59. Given that significant IOP reductions with BBFC are still seen at 8 am (10 hours after dosing), it is likely that the nocturnal IOP-lowering efficacy of BBFC is being conferred by the brinzolamide, not the brimonidine, component 60,61.…”

Section: Efficacy Of Bbfcmentioning

confidence: 99%

See 1 more Smart Citation

Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus

Nguyen

2014

PPA

View full text Add to dashboard Cite

Glaucoma is one of the leading causes of blindness and is characterized by optic nerve damage that results in visual field loss. Elevated intraocular pressure (IOP) has been associated with glaucoma progression; thus, IOP-lowering medications are the standard of care for glaucoma. Guidelines suggest monotherapy with IOP-lowering agents such as β-blockers (eg, timolol), prostaglandin analogs, carbonic anhydrase inhibitors (eg, brinzolamide), and α2-receptor agonists (eg, brimonidine). However, monotherapy may provide insufficient IOP reduction in some patients, thereby necessitating the use of multiple IOP-lowering medications. Multidrug regimens may be complex, may increase the risk of preservative-related ocular symptoms, and may potentially reduce overall drug exposure as a consequence of drug washout during closely timed sequential administrations; these difficulties may reduce overall drug efficacy and decrease patient persistence and adherence with multidrug treatment regimens. Fixed-combination medications that provide two IOP-lowering therapies within a single solution are available and may overcome some of these challenges. However, all currently available fixed combinations combine timolol with another IOP-lowering agent, indicating that additional fixed-combination alternatives would be beneficial. To meet this demand, a novel fixed combination of brinzolamide 1% and brimonidine 0.2% (BBFC) has recently been developed. In two randomized, double-masked, multinational clinical trials, BBFC had greater IOP-lowering efficacy than brinzolamide or brimonidine monotherapy after 3 months of treatment in patients with open-angle glaucoma or ocular hypertension. In both studies, the overall safety profile of BBFC was consistent with that of brinzolamide and brimonidine. Comparative studies with BBFC versus other IOP-lowering monotherapy and fixed-combination medications are not available, but the IOP reductions observed with BBFC are similar to or greater than those reported in the literature for other glaucoma treatments; thus, BBFC provides an additional fixed-combination therapeutic option for patients who require further efficacious IOP reduction and improved convenience and tolerability versus concomitant administration of two separate medications.

show abstract

Section: Efficacy Of Bbfcmentioning

confidence: 86%

Section: Efficacy Of Bbfcmentioning

confidence: 99%

Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus

Nguyen

2014

PPA

View full text Add to dashboard Cite

show abstract

“…DTFC exerts better e cacy than any single medication. Studies suggested that DTFC could help decrease IOP signi cantly in patients with POAG [23][24][25][26][27][28][29][30][31]. However, no systematic review has investigated the e cacy and safety of DTFC in treating POAG.…”

Section: Eligibility Criteriamentioning

confidence: 99%

Dorzolamide/Timolol-Fixed Combination For Primary Open-Angle Glaucoma: A Protocol For Systematic Review

Qi¹,

Liu²,

Sun³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Primary open-angle glaucoma (POAG) is a very common disorder, and it is the second leading cause that results in blindness worldwide after cataracts. Previous studies have reported that dorzolamide/timolol-fixed combination (DTFC) can be used in treating POAG. However, there are still inconsistent results. Thus, this study will systematically investigate the efficacy and safety of DTFC on POAG. Methods: A comprehensive search will be carried out in Cochrane Library, MEDLINE, EMBASE, CINAHI, ACMD, China National Knowledge Infrastructure, and WANGFANG database from origin to the present. There are no limitations related to the language and publication status. Only randomized controlled trials that assessed the efficacy and safety of DTFC for the treatment of POAG will be included. Two researchers will independently undertake record selection, data extraction, and study quality assessment. Any divisions will be solved by discussion with a third researcher. We will perform statistical analysis using RevMan 5.3 software Discussion: This study will summarize the present evidence to identify the efficacy and safety of DTFC in treating POAG through mean intraocular pressure, best corrected visual acuity, contrast sensitivity, bioelectric activity of the retina, rate of progression of glaucoma, quality of life, and adverse events. The results of this study will help to determine whether DTFC is effective and safety for the treatment of POAG.Systematic review registration: PROSPERO CRD42020170531.

show abstract

“…It had also been suggested that DTFC may provide better 24-hour efficacy than brimonidine/timolol fixed combination (BTFC) in primary open-angle glaucoma (POAG) [120]. …”

Section: Contemporary Pharmacological Management Of Glaucomamentioning

confidence: 99%

Medical Management of Glaucoma in the 21st Century from a Canadian Perspective

Harasymowycz

Birt

Gooi

et al. 2016

Journal of Ophthalmology

100

View full text Add to dashboard Cite

Glaucoma is a medical term describing a group of progressive optic neuropathies characterized by degeneration of retinal ganglion cells and retinal nerve fibre layer and resulting in changes in the optic nerve head. Glaucoma is a leading cause of irreversible vision loss worldwide. With the aging population it is expected that the prevalence of glaucoma will continue to increase. Despite recent advances in imaging and visual field testing techniques that allow establishment of earlier diagnosis and treatment initiation, significant numbers of glaucoma patients are undiagnosed and present late in the course of their disease. This can lead to irreversible vision loss, reduced quality of life, and a higher socioeconomic burden. Selection of therapeutic approaches for glaucoma should be based on careful ocular examination, patient medical history, presence of comorbidities, and awareness of concomitant systemic therapies. Therapy should also be individualized to patients' needs and preferences. Recent developments in this therapeutic field require revisiting treatment algorithms and integration of traditional and novel approaches in order to ensure optimal visual outcomes. This article provides an overview of recent developments and practice trends in the medical management of glaucoma in Canada. A discussion of the surgical management is beyond the scope of this paper.

show abstract

Twenty-four hour efficacy with the dorzolamide/timolol-fixed combination compared with the brimonidine/timolol-fixed combination in primary open-angle glaucoma

Cited by 24 publications

References 33 publications

Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus

Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus

Dorzolamide/Timolol-Fixed Combination For Primary Open-Angle Glaucoma: A Protocol For Systematic Review

Medical Management of Glaucoma in the 21st Century from a Canadian Perspective

Contact Info

Product

Resources

About